アドリアマイシン封入リポソームの院内製剤化及び安定性

概要

論文の詳細を見る
Adriamycin (ADM), an important antitumor agent with a wide spectrum, has dosage limitation in its clinical use because of its dose-related cardiotoxicity. One of the approaches to minimize this toxicity is to encapsulate ADM in liposomes. We have developed an injectable liposomal preparation in which ADM is entrapped (ADM-Lip) for intrahospital use. ADM was entrapped in negatively charged liposomes which were composed of egg phosphatidylcholine, cholesterol, and phosphatidylserine (molar ratio of 5:4:1). Effective ADM entrapment (rate) in our intrahospital preparation was approximately 60%. The liposomal particle size, as measured by the dynamic light scattering method, was 203±90nm. ADM-Lip was sterilized through a polycarbonate membrane filter with a pore diameter of 0.2μm.
日本医療薬学会の論文
1990-02-20